Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist.

Identification of SR3335 (ML-176): a synthetic RORα selective inverse agonist.
复制标题

DOI:
10.1021/cb1002762
复制
发表时间:
2011-03-18
影响因子:
4
通讯作者:
Burris, Thomas P.
Burris, Thomas P.
中科院分区:
生物学2区
文献类型:
--
作者:
Kumar, Naresh;Kojetin, Douglas J.;Solt, Laura A.;Kumar, K. Ganesh;Nuhant, Philippe;Duckett, Derek R.;Cameron, Michael D.;Butler, Andrew A.;Roush, William R.;Griffin, Patrick R.;Burris, Thomas P.

文献摘要

参考文献

被引文献

相似文献

几种核受体(NR)仍然被表征为孤儿受体,因为这些蛋白质的配体尚未被鉴定。视黄酸受体相关受体(ROR)没有明确的生理配体。在此,我们描述了选择性RORα合成配体SR 3335(ML-176)的鉴定。SR 3335直接与RORα结合,但不与其他ROR结合,在基于细胞的试验中作为RORα的选择性部分反向激动剂发挥作用。此外,SR 3335抑制HepG 2中参与肝硬化发生的内源性RORα靶基因的表达,包括葡萄糖-6-磷酸酶和磷酸烯醇式丙酮酸羧激酶。药代动力学研究表明,小鼠腹腔注射SR 3335后显示出合理的暴露量。我们使用饮食诱导的肥胖(DIO)小鼠模型评估SR 3335抑制体内脂肪生成的能力,其中小鼠用15 mg/kg b.i.d.,腹膜内注射6天,然后进行丙酮酸耐受性试验。SR 3335给药小鼠在丙酮酸激发后显示出较低的血糖水平,这与抑制新生血管形成一致。因此,我们已经确定了第一个选择性合成的RORα反向激动剂,这种化合物可以用作化学工具,以探测这种受体在体外和体内的功能。此外,我们的数据表明,RORα反向激动剂可能具有抑制2型糖尿病患者肝葡萄糖生成升高的效用。
Several nuclear receptors (NRs) are still characterized as orphan receptors since ligands have not yet been identified for these proteins. The retinoic acid receptor-related receptors (RORs) have no well-defined physiological ligands. Here, we describe the identification of a selective RORα synthetic ligand, SR3335 (ML-176). SR3335 directly binds to RORα, but not other RORs, and functions as a selective partial inverse agonist of RORα in cell-based assays. Furthermore, SR3335 suppresses the expression of endogenous RORα target genes in HepG2 involved in hepatic gluconeogenesis including glucose-6-phosphatase and phosphoenolpyruvate carboxykinase. Pharmacokinetic studies indicate that SR3335 displays reasonable exposure following an i.p. injection into mice. We assess the ability of SR3335 to suppress gluconeogenesis in vivo using a diet induced obesity (DIO) mouse model where the mice where treated with 15 mg/kg b.i.d., i.p. for 6-days followed by a pyruvate tolerance test. SR3335 treated mice displayed lower plasma glucose levels following the pyruvate challenge consistent with suppression of gluconeogenesis. Thus, we have identified the first selective synthetic RORα inverse agonist and this compound can be utilized as a chemical tool to probe the function of this receptor both in vitro and in vivo. Additionally, our data suggests that RORα inverse agonists may hold utility for suppression of elevated hepatic glucose production in type 2 diabetics.
DOI: 10.1074/jbc.m710526200
发表时间: 2008-06-27
影响因子: 4.8
作者:
Lau, Patrick;Fitzsimmons, Rebecca L.;Muscat, George E. O.
通讯作者: Muscat, George E. O.
DOI: 10.1621/nrs.07003
发表时间: 2009
期刊: Nuclear receptor signaling
影响因子: --
作者:
Jetten AM
通讯作者: Jetten AM
DOI: 10.1210/en.2009-0800
发表时间: 2010-07-01
期刊: ENDOCRINOLOGY
影响因子: 4.8
作者:
Kumar, Naresh;Solt, Laura A.;Burris, Thomas P.
通讯作者: Burris, Thomas P.
DOI: 10.1021/jo01015a009
发表时间: 1965-01-01
影响因子: 3.6
作者:
FARAH, BS;GILBERT, EE;SIBILIA, JP
通讯作者: SIBILIA, JP
DOI: 10.1124/mol.109.060905
发表时间: 2010-02-01
影响因子: 3.6
作者:
Kumar, Naresh;Solt, Laura A.;Griffin, Patrick R.
通讯作者: Griffin, Patrick R.